Lyka Labs Limited (LYKALABS) Price & Analysis

Compare

1 Followers

LYKALABS Stock Chart & Stats

₹94.40

-₹1.55(-0.97%)

At close: Jan 08 4:00 PM EST

₹94.40

-₹1.55(-0.97%)

Day’s Range― - ―

52-Week Range₹60.00 - ₹128.60

Previous CloseN/A

Volume78.41K

Average Volume (3M)3.02K

Market Cap

₹2.18B

Enterprise Value₹2.51B

Total Cash (Recent Filing)₹18.36M

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)―

Beta1.20

Next Earnings

Jun 02, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.00

Shares Outstanding35,690,000

10 Day Avg. Volume1,252

30 Day Avg. Volume3,017

Financial Highlights & Ratios

PEG Ratio-0.12

Price to Book (P/B)3.58

Price to Sales (P/S)2.64

P/FCF Ratio-26.96

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Strong Revenue GrowthSustained high revenue growth indicates expanding product uptake and broader market penetration in formulations and exports. Over 2-6 months this supports scale advantages, better fixed-cost absorption and provides a foundation for reinvesting in R&D, capacity or distribution to entrench competitive position.

Improved EBIT / EBITDA MarginsRising EBIT and EBITDA margins show the company is extracting more profit per rupee of sales through cost control or better mix. Margin expansion is durable if driven by structural efficiencies, manufacturing scale, or higher-value formulations, improving cash generation potential over multiple quarters.

Strengthened Equity, Lower LeverageA stronger equity base and reduced debt-to-equity ratio enhance financial resilience and borrowing capacity. Overcoming prior leverage improves ability to fund capex, withstand sector cycles, and pursue partnerships or exports without excessive refinancing risk, supporting medium-term strategic initiatives.

Bears Say

High Overall LiabilitiesPersistently high liabilities constrain financial flexibility and raise refinancing and counterparty risks. Even with improved equity, elevated obligations can limit investment, increase interest burden if rates rise, and reduce ability to fund strategic moves without additional external financing over the coming quarters.

Negative Free Cash FlowNegative free cash flow driven by heavy capex means reported profits aren't converting into surplus cash. This can limit dividends, debt paydown, or organic funding for growth, forcing reliance on external financing or equity issuance and elevating execution risk for long-term capacity or product investments.

Weak Cash Conversion Vs Net IncomeLow operating cash flow relative to net income signals weak earnings quality and working capital strain. If sustained, it undermines the sustainability of margins and makes the business more vulnerable to supplier or customer timing, limiting ability to self-fund operations and strategic initiatives over multiple quarters.

Lyka Labs Limited News

Lyka Labs Says NCLT Reserves Order on Amalgamation Scheme After FEMA Compliance Filing

Lyka Labs Limited ( ($IN:LYKALABS) ) just unveiled an announcement. Lyka Labs Limited has updated exchanges on the...

6d ago

Lyka Labs Confirms SEBI Dematerialisation Compliance for December Quarter

Lyka Labs Limited ( ($IN:LYKALABS) ) has provided an update. Lyka Labs Limited has reported that its registrar...

2M ago

Lyka Labs Updates on Amalgamation Process

Lyka Labs Limited ( ($IN:LYKALABS) ) has issued an announcement. Lyka Labs Limited has provided an update on...

5M ago

Lyka Labs Promoters Declare No Share Encumbrance

Lyka Labs Limited ( ($IN:LYKALABS) ) has issued an update. Lyka Labs Limited, a company involved in the...

11M ago

LYKALABS FAQ

What was Lyka Labs Limited’s price range in the past 12 months?

Lyka Labs Limited lowest stock price was ₹60.00 and its highest was ₹128.60 in the past 12 months.

What is Lyka Labs Limited’s market cap?

Lyka Labs Limited’s market cap is ₹2.18B.

When is Lyka Labs Limited’s upcoming earnings report date?

Lyka Labs Limited’s upcoming earnings report date is Jun 02, 2026 which is in 96 days.

How were Lyka Labs Limited’s earnings last quarter?

Lyka Labs Limited released its earnings results on Jan 29, 2026. The company reported ₹0 earnings per share for the quarter, the consensus estimate of N/A by ₹0.

Is Lyka Labs Limited overvalued?

According to Wall Street analysts Lyka Labs Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Lyka Labs Limited pay dividends?

Lyka Labs Limited does not currently pay dividends.

What is Lyka Labs Limited’s EPS estimate?

Lyka Labs Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Lyka Labs Limited have?

Lyka Labs Limited has 35,690,000 shares outstanding.

What happened to Lyka Labs Limited’s price movement after its last earnings report?

Lyka Labs Limited reported an EPS of ₹0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went down -3.741%.

Which hedge fund is a major shareholder of Lyka Labs Limited?

Currently, no hedge funds are holding shares in IN:LYKALABS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Lyka Labs Limited

Lyka Labs Limited, a pharmaceutical company, engages in development, manufacture, and marketing of pharmaceutical formulations and active pharmaceutical ingredients across various therapeutic segments in India. The company manufactures and sells various formulations, including emollient, topical steroid, antifungal agent, topical anti-bacterial, acne management, dermatological formulation, pain killer, anti-aging, cleansing lotion, hair care, anti-dandruff shampoo, sunscreen, anti-acne, cosmeceutical, anti-oxidant, proton pump inhibitor, anti-malarial, anti-bacterial, corticosteroid hormones, cephalosporin, dry powder injection, muscle relaxant, bone resorption inhibitor, anti-oxidant/liver disease, antibiotic, and lyophilized products. It also offers contracted manufacturing services to various large pharmaceutical companies; and medical and technical assistance in the areas of manufacturing know how and manufacturing facilities, as well as technical data, such as molecule stability testing data, impurity profile, and BA/BE clinical study data. In addition, it provides products and services in therapeutic categories, such as intensive care, gastroenterology, anti-infective, anti-fungal, surgery care, cosmetologist, urology, wound care, and anesthesia, as well as deals in pharmaceutical products. The company offers its products in various formulations, including injections, creams, ointments, gels, and lotions. It also exports its products to Bangladesh, Combodia, Congo, Costa Rica, Peru, Romania, Russia, Sri Lanka, Sudan, Ukraine, Venezuela, and Vietnam. Lyka Labs Limited was incorporated in 1976 and is based in Mumbai, India.